Clinical Trials

Small Cell Lung Carcinoma

NCT04745689 2025-12-10

TAZMAN

31 enrolled 15 charts

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04397003 2025-10-22

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

6 enrolled

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

46 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05796089 2025-08-26

CHEST RT

35 enrolled

Small Cell Lung Carcinoma

NCT05617963 2025-06-15

DURVALUNG

Phase 2 Recruiting

100 enrolled

Small Cell Lung Carcinoma

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Phase 2 Enrolling by invitation

Small Cell Lung Carcinoma

NCT06419179 2025-05-20

GUIDANCE

29 enrolled

Small Cell Lung Carcinoma

NCT04870112 2025-04-17

SCope-D1

Phase 1 Terminated

18 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03509012 2025-01-14

CLOVER

Phase 3 Not yet recruiting

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06719336 2024-12-05

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

182 enrolled

Small Cell Lung Carcinoma

NCT04951115 2024-11-26

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Phase 2 Terminated

6 enrolled 13 charts

Small Cell Lung Carcinoma

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

BreastDermatologicGenitourinaryGynecologicThoracic

60 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05572476 2024-06-05

LURBIMUNE

Phase 2 Withdrawn

Small Cell Lung Carcinoma

NCT06223711 2024-04-05

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Phase 2 Recruiting

43 enrolled

Small Cell Lung Carcinoma

NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2 Terminated

3 enrolled 13 charts

CNSThoracic

Brain Neoplasms, Small Cell Lung Carcinoma

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

30 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04361825 2024-01-03

SUKSES-N4

Phase 2 Completed

42 enrolled

Small Cell Lung Carcinoma

NCT04985851 2023-12-01

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Phase NA Unknown

90 enrolled

Small Cell Lung Carcinoma

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

1 enrolled

Small Cell Lung Carcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05484583 2022-08-05

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Phase 2 Not yet recruiting

58 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

60 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

18 enrolled 13 charts

Small Cell Lung Carcinoma

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

33 enrolled

Small Cell Lung Carcinoma

NCT03585998 2020-03-02

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

51 enrolled

Small Cell Lung Carcinoma

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

2 enrolled